title: Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival.
abstract: OBJECTIVE
  Based on the success of hematopoietic stem-cell transplantation (HSCT) for multiple myeloma, HSCT is being used to treat patients with primary systemic amyloidosis (AL). This article addresses the extent to which eligibility to undergo HSCT is a favorable prognostic feature and explores prognostic factors within the subset of eligible patients.
  
  
  METHODS
  The Mayo Clinic amyloid database was queried for all patients with AL seen at the Mayo Clinic from 1983 through 1997 who would have been eligible for peripheral-blood stem-cell transplantation. Inclusion criteria included biopsy-proven amyloid, symptomatic disease, absence of a clinical diagnosis of multiple myeloma, age < or = 70 years, cardiac interventricular septal thickness < or = 15 mm, cardiac ejection fraction more than 55%, serum creatinine < or = 2 mg/dL, and direct bilirubin < or = 2.0 mg/dL.
  
  
  RESULTS
  Median age was 56 years (range, 25 to 70) with 79 (34%) older than 60 years. One hundred patients had early cardiac involvement; 41, hepatic involvement; 167, renal involvement; and 39, nerve involvement. The 229 patients have had a median follow-up of 52 months, and 151 have died. The median survival was 42 months with 5- and 10-year survival rates of 36% and 15%, respectively. Important predictors of survival were size of M-component in 24-hour urine, number of involved organs, alkaline phosphatase, performance score, and weight loss.
  
  
  CONCLUSIONS
  The same patients who are eligible for HSCT are a good-risk population who do relatively well with chemotherapy (median survival, 42 months), substantially better than the expected median survival of 18 months for all patients with AL. A randomized trial is needed to assess the true effect of HSCT.
authors.affiliation: Division of Hematology and Internal Medicine, and Section of Biostatistics, Mayo Clinic, Rochester, MN 55905, USA. dispenzieri.angela@mayo.edu
authors.forename: A
authors.initials: A
authors.lastname: Dispenzieri
authors.forename: M Q
authors.initials: MQ
authors.lastname: Lacy
authors.forename: R A
authors.initials: RA
authors.lastname: Kyle
authors.forename: T M
authors.initials: TM
authors.lastname: Therneau
authors.forename: D R
authors.initials: DR
authors.lastname: Larson
authors.forename: S V
authors.initials: SV
authors.lastname: Rajkumar
authors.forename: R
authors.initials: R
authors.lastname: Fonseca
authors.forename: P R
authors.initials: PR
authors.lastname: Greipp
authors.forename: T E
authors.initials: TE
authors.lastname: Witzig
authors.forename: J A
authors.initials: JA
authors.lastname: Lust
authors.forename: M A
authors.initials: MA
authors.lastname: Gertz
mesh_terms: D000328:Adult; D000368:Aged; D000686:Amyloidosis / Q000628:therapy*; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D011379:Prognosis; D016019:Survival Analysis